What is Labviva?
Founded in 2017, Labviva operates as a sophisticated digital ecosystem designed to streamline the purchasing experience for researchers and laboratory managers. The platform functions as a centralized hub that integrates scientific data with product catalogs, allowing for a seamless procurement process that reduces administrative friction. By connecting researchers directly with a vast network of suppliers, Labviva addresses the historical inefficiencies inherent in life science supply chains, such as fragmented ordering systems and lack of transparency in product availability.
The company's market position is defined by its unique ability to harmonize complex scientific requirements with enterprise-grade purchasing tools. As the life sciences industry continues to prioritize digital transformation, Labviva's infrastructure provides a critical layer of connectivity that enhances operational efficiency for both academic and commercial research organizations.
How much funding has Labviva raised?
Labviva has raised a total of $28M across 2 funding rounds:
Angel/Seed
$8M
Series A
$20M
Angel/Seed (2021): $8M with participation from Glasswing Ventures, Senator Investment Group, and B Capital Group
Series A (2023): $20M led by Biospring Partners, Senator Investment Group, Glasswing Ventures, and B Capital Group
Key Investors in Labviva
Biospring Partners
Biospring specializes in partnering with technology-enabled, EBITDA-positive pharma services businesses that focus on innovation in manufacturing and clinical trial services.
Senator Investment Group
Founded in 2008 and based in New York City, Senator Investment Group is a company that focuses on asset allocation for a variety of public equity and fixed income markets globally.
Glasswing Ventures
Glasswing Ventures invests in visionary, early-stage founders who are leveraging AI and frontier technology to transform enterprise and security markets.
What's next for Labviva?
With the successful closure of this major strategic investment, Labviva is well-positioned to accelerate its market expansion and deepen its technological capabilities. The company is expected to leverage this capital to enhance its platform's integration features, potentially expanding its reach into new geographic markets and broadening its supplier network. As the firm moves into its next phase of growth, the focus will likely shift toward optimizing the user experience for large-scale enterprise clients and further integrating AI-driven insights into the procurement lifecycle.
The continued support from high-profile investors suggests a strong confidence in Labviva's long-term vision to become the standard operating system for life science procurement. By maintaining its commitment to innovation and operational excellence, the company is poised to disrupt traditional procurement models and solidify its status as a leader in the life science technology space.
